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ABSTRACT 
Growth Hormone (GH) and Prolactin (PRL) are critical regulators of body growth and 
metabolism. Secretion and actions of GH and PRL are regulated at several levels and by 
different factors. The biological actions of these hormones are initiated by their binding to the 
respective membrane bound receptors of GH and PRL (GHR and PRLR). Several hormone 
systems are characterized by changes in target tissue sensitivity. Key factors in hormone 
sensitivity include the number of particular receptors and the duration of receptor activated 
intracellular signals. A common theme concerning this is e.g. that tyrosine phosphorylated 
intracellular proteins become inactivated by tyrosine phosphatases or by proteasomal 
breakdown.   
In this thesis a particular focus is put on two different proteins, Suppressors of Cytokine 
Signaling2 (SOCS2) and Tuberous Sclerosis Complex2 (TSC2) that uniquely impinge on 
JAK-STAT activation and on mTOR activation. 
Study I. We explored the influence of SOCS2 on glucose metabolism by using a mouse 
model of diabetes induced by multiple low dose streptozotocin (MLDSTZ). Pancreatic islets 
from untreated SOCS2-/- mice appeared larger than in wild-type (WT) controls, which could 
explain the augmented serum insulin levels observed in SOCS2-/- mice. Pancreatic islets, 
derived from SOCS2-/- mice showed increased GHR and PRLR staining, which suggest a 
higher sensitivity to GH/PRL-STAT5 signals in SOCS2-/- than in WT-derived β-cells. Our 
results suggest that SOCS2 ablation can partly overcome β-cell destruction induced by 
MLDSTZ. 
Study II and III. In these studies we aimed to investigate the relevance of PRL in two 
different human tumors, i.e.lymphangioleiomyomatosis (LAM) and glioblastoma (GBM), by 
analyzing features of the PRLR and the effect of a novel PRLR antagonist (PRLRA) in such 
tumors. Reduction of TSC2 (the disease causing gene in LAM) increased PRLR levels in 
LAM cells and PRL stimulated LAM cell proliferation; an effect that could be blocked with 
the PRLRA. In GBM, PRLR was detectable in cultured GBM cells as well as in tissue 
sections from patients with GBM. In cell culture GBM studies, PRL treatment increased 
STAT5 phosphorylation as well as cell invasion and both effects could be blocked by the 
PRLRA.  
In summary, our studies indicate that the tissue sensitivity to GH/PRL is regulated by SOCS2 
and TSC2 proteins. Since both SOCS2 and TSC2 have links to different disorders, an 
increased GH/PRL sensitivity in such conditions could play a functional role. To block an 
increased PRL sensitivity we have developed a novel PRLRA and demonstrated its efficacy 
in cell cultures.   
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1 INTRODUCTION 
In multicellular organisms, distinct populations of cells coordinate with one another to 
accomplish roles, which no single cell could carry out on its own. A crucial aspect of this 
feature of multicellular organisms is inter-cellular communication, involving signals either 
from the environment or from other cells. In order to result in the appropriate cellular 
response, these signals must be transmitted across the cell membrane. Such signaling 
processes frequently involve receptor proteins that contact both the exterior and interior of the 
cell, and only cells that have the correct receptors on their surfaces will respond to any 
particular signal. These signals could either be from the cell itself (autocrine), from a 
neighboring cell (paracrine), or may travel through the bloodstream from another specialized 
cell in the body (endocrine). These particular signaling molecules are called hormones and 
cytokines. 
1.1 PROLACTIN 
A substance from extracts of bovine pituitary glands able to promote milk secretion was first 
described in 1928 by Stricker and Grueter. This substance was further purified and identified 
as prolactin (PRL) in 1933 by Riddle and Bates, and was named for its stimulatory action on 
lactation [1]. PRL, also known as lactogen or mammotropin, is a polypeptide hormone 
secreted by the acidophilic lactotroph cells located in the adenohypophysis of the pituitary 
gland. In addition to its stimulatory effects on mammary gland development and lactation, 
PRL is known to exert more than 300 different biological functions related to reproduction, 
development, growth, metabolism, immunomodulation, osmoregulation and behavior [2,3]. 
1.1.1 Gene, structure and variants 
PRL is a member of the PRL/Growth Hormone (GH)/Placental Lactogen (PL) hormone 
family. All of these hormones share genomic, structural and biological features [4], and 
belong to an extended family of proteins known as hematopoietic cytokines [5]. The genes 
encoding PRL, GH and PL were derived from one common ancestral gene by gene re-
duplication [6]. The gene encoding PRL is found in all vertebrates and is located on 
chromosome 6 in humans [7]; it consists of five exons and four introns [8] with an additional 
noncoding “exon1a” which is only transcribed in extra-pituitary tissues [9]. The mature form 
of the 23 kDa PRL protein consists of 199 amino acids in humans, and has four α-helixes 
arranged in an up-up-down-down style [10]. 
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Unlike humans, rodents express several PRL-encoding genes, which are located on 
chromosomes 13 and 17 in mice and rats, respectively. In humans and other primates, but not 
in rodents, research has demonstrated expression of the PRL gene in several extra-pituitary 
tissues [11,12]. This is because of the presence of an alternative promoter located 5.8 kb 
upstream of the pituitary transcription start site which drives extra-pituitary PRL expression 
[13–16]. Although different promoters control PRL expression in pituitary and extra-pituitary 
tissues, the human PRL protein sequence is identical regardless of the site of production [17]. 
Extra-pituitary PRL production is well recognized, and although studies indicate a 
proliferative/anti-apoptotic role for this autocrine/paracrine-produced PRL, the role of extra-
pituitary PRL production in humans requires further investigation [12]. 
In addition to 23kDa PRL, other larger forms of the protein (>100kDa) have been identified 
in the circulation. These include the 23kDa PRL complexed with IgG antibodies forming a 
big complex; however, this PRL possess lower biological activity compared to the 
monomeric mature form [18]. Macroprolactinemia is a heterogeneous condition characterized 
by the predominance of higher molecular mass PRL and the production of anti-PRL 
autoantibodies that reduce PRL bioactivity and delay its clearance [19]. Other well-
characterized 14-, 16-, 22-kDa prolactin protein variants are generated by proteolytic 
cleavage of the 23kDa protein [10]. 
1.1.2 Synthesis and regulation of secretion 
The lactotroph cells of the anterior pituitary gland are considered to be the primary source of 
PRL in the body. However, when pituitary-derived PRL synthesis and/or release is impaired, 
humans are not deprived from the extra-pituitary produced PRL since their transcriptional 
regulation is not similar. The production of PRL by lactotrophs is mainly regulated by the 
pituitary transcription factor Pit-1 [20]. The transcription and secretion of PRL hormone from 
the lactotrophs are controlled, to a large extent, by hypothalamus. In primates, this 
hypothalamic regulation is mainly inhibitory, in contrast to what is seen with other pituitary 
hormones. Dopamine, a neurotransmitter released into portal blood by hypothalamic neurons, 
acts as one major inhibiting factor on PRL secretion, through its binding to type-2 dopamine 
receptors, which suppresses both the synthesis and secretion of PRL from pituitary 
lactotrophs. PRL itself, along with other factors, acts in a short feedback loop to inhibit 
dopamine release and maintaining PRL homeostasis [21,22]. In addition to tonic inhibition by 
the hypothalamus, PRL production and release is positively regulated by several hormones, 
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including thyroid-releasing hormone, oxytocin, gonadotropin-releasing hormone, estrogen, 
prolactin-releasing peptide and vasoactive intestinal polypeptide [10,23]. 
PRL secretion in humans is primarily highest during sleep and is lowest during the waking 
hours, following a true circadian rhythm generated in a constant environment regardless of 
the sleep rhythm [24]. The secretion shows sexual dimorphism, having a higher amplitude 
and a more continuous secretion in females compared to males, who have a more intermittent 
secretion pattern [25]. This gender-specific difference in the mode of PRL secretion could at 
least partly be linked to sex-steroids. Other non-gender specific factors that regulate PRL 
release include light, stress, sex, suckling, odor and sound. PRL mediates its action on target 
tissues by binding to the membrane-bound PRL receptor (PRLR). 
1.2 GROWTH HORMONE  
As mentioned above, GH also known as somatotropin, somatropin or somatotrope hormone 
belongs to the same family as PRL. GH is a polypeptide hormone and in its most prevalent 
form has a size of 22 kDa, consisting of 191 amino acids in humans [26]. The primary site for 
GH biosynthesis is the somatotropic cells of the anterior pituitary gland, where its 
transcription is mainly regulated by Pit-1 [27]. The release of GH from the secretory granules 
in somatotropic cells is under a balanced control of two neuroendocrine peptides from the 
hypothalamus; growth hormone-releasing hormone (GHRH) and growth hormone-inhibiting 
hormone [28,29]. 
GH secretion, in primates, is pulsatile and occurs primarily during sleep [30]. The secretion is 
sexually dimorphic, with high nocturnal pulses and small daytime pulses in males but a more 
continuous secretory pattern or frequent pulses of similar amplitude in females [31]. These 
sex differences in the GH secretory pattern may explain the differences in growth between 
males and females. Once GH is released into the bloodstream and reaches its target organs, it 
binds to its receptor, the growth hormone receptor (GHR). GHR signaling triggers the 
expression and release of insulin-like growth factor-1 (IGF-1), which mediates some of the 
actions of GH [32]. 
1.3 PROLACTIN AND GROWTH HORMONE RECEPTORS 
PRL/GH hormones exert their actions on target cells via specific membrane-bound receptors, 
PRLR and GHR. These, along with other receptors for ligands such as leptin, leukemia-
inhibiting factor, and erythropoietin, are all members of the type 1 cytokine receptor family 
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[33]. PRLR and GHR share several structural and functional features despite possessing a 
limited sequence homology. Thus they contain three domains: an extracellular domain (ECD) 
that binds the ligand, a single trans-membrane domain (TD) and intracellular domain (ICD) 
[4,34–36]. Two separate binding sites on the ligand molecule each bind to one receptor 
protein in a two-step process in which site 1, on the ligand molecule, binds to one receptor 
molecule, after which a second receptor molecule binds to site 2 on the ligand. This leads to 
the formation of a homodimer consisting of one ligand molecule and two receptor molecules 
[35]. Initially, it was believed that PRL/GH dimerize two receptor molecules [37,38], while 
more recent studies have suggested that both PRLR and GHR are already present as 
preformed dimers in the membrane [39,40]; PRL/GH binding then only induces a 
conformational change in the receptor to activate the intracellular part of the PRLR/GHR and 
initiate signaling (Figure 1) [41].  
 
Figure 1. Models for PRLR/GHR activation. (A) The early model for PRLR/GHR activation 
was based on ligand-induced receptor dimerization. (B) It is now believed that the receptor 
exists as a dimer in the membrane; this binds the ligand, causing a rotation in the receptor 
domains that triggers downstream signaling. Figure adapted from a review by Yahia A Kaabi 
[42]. 
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The structural and conformational changes induced by ligand binding to the receptor have 
been extensively reviewed by C.L. Brooks [43]. The GH binds to both GH and PRL 
receptors, whereas PRL only binds to the PRLR.  [34]. 
PRLR is encoded by a single gene located on chromosome 5, and differential RNA splicing 
or posttranslational modifications lead to several tissue-specific variants or isoforms [2,35]. 
Basically, PRLR has three isoforms that differ in length to give long, intermediate and short 
forms of the protein. All isoforms share an identical ECD and TD but differ in the ICD [36]. 
In humans, one long, one intermediate and two short isoforms have been described, and in 
mice, one long and three short isoforms have been identified, while all of the major isoforms 
have been identified in rats [10]. Like all members of the class 1 cytokine receptor family, 
PRLR/GHR lacks intrinsic kinase activity; instead, the receptor molecule associates with an 
intracellular tyrosine kinase. Cytokine receptors are able to initiate signaling through several 
different intracellular signaling pathways. 
1.4 BIOLOGICAL ACTIONS OF PROLACTIN AND GROWTH 
HORMONE  
PRLR and GHR are expressed in several organs and tissues in vertebrates, and there is a 
tissue-specific variability in receptor expression levels. Many physiological actions have been 
attributed to GH and PRL, some of which will be listed below. In many cases, these 
biological functions are similar between different species, but particularly in the case of 
PRL’s actions, large species-specific differences in biological functions have been observed.    
1.4.1 Mammary gland development 
One important function of PRL is related to mammary gland development and lactation. 
During pregnancy, the mammary glands are under the control of multiple factors including 
insulin, glucocorticoids, GH, PRL, PL, estrogen and progesterone [44]. However, the final 
extensive and diffuse branching of the gland’s ducts and alveoli is under the direct control of 
PRL and progesterone [45]. Knocking down of PRL and/or PRLR expression result in total 
absence of the lobulo-alveolar unit in mammary tissue [46]. PRL not only contributes to 
mammary gland development, but also stimulates lactogenesis (milk production) [47]. 
1.4.2 Luteal function  
Studies on rodent models demonstrate that PRL has dual actions in the corpus luteum. PRL 
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has been recognized as a luteotropic and luteolytic hormone. The luteotropic action of PRL 
involves stimulation of progesterone production by luteal cells [48]. Progesterone is 
important for implantation of the fertilized ovum and maintenance of pregnancy. The 
luteolytic action of PRL involves induced programmed cell death in the corpora lutea [49]. In 
humans, studies show a correlation between high PRL levels and the inhibition of granulosa 
cell luteinization [49]. Furthermore, a direct PRL action on oocyte development and 
maturation has been reported [50]. 
1.4.3 Male sex organs 
PRL is also produced in the male pituitary gland, despite the fact that PRL is primarily 
considered as a lactating hormone. PRLR is present on the plasma membranes of testicular 
interstitial cells including Leydig cells, as well as on Sertoli cells and the cells of the germinal 
epithelium in the testis. In Leydig and Sertoli cells, PRL has been shown to increase 
luteinizing hormone and follicle-stimulating hormone receptors expression levels, 
respectively [51,52], with a significant effects on the proliferation and metabolism of these 
cells [53]. In general, PRL stimulates testicular functions in mammals, stimulating both 
testosterone and estradiol secretion from Leydig cells [54], and increasing energy metabolism 
in epididymal cells and spermatozoa [55]. 
Another well-defined male-specific effect of PRL in rodents and humans concerns the 
prostate gland. In 1997, a research group confirmed the local production of PRL in human 
prostate tissues, and also reported the presence of PRLR in the secretory epithelium of the 
human prostate [56]. Several studies involving rodent models and human prostate cell lines 
support a role for PRL as a growth factor in the prostate [57].  
1.4.4 Growth and cell proliferation 
As mentioned above, cells in the anterior pituitary gland produce GH and PRL. These 
proteins belong to the same cytokine family, although it is clear that they have distinct and 
separate biological effects. One example of this is that the effect of GH on longitudinal 
growth does not involve PRL [58]. The role of GH to promote longitudinal growth depends 
on IGF-1 produced by the liver or produced locally in the growth zone [59]. IGF-1 is often 
used as a clinical marker for GH secretion. It is, however, clear that not all GH effects are 
dependent on IGF-1 [60]. 
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On the other hand, PRL has a stimulatory role on certain tissues including the liver, ovary and 
uterus. PRL stimulates turnover of, and/or activates, a number of factors in liver cells, such as 
protein kinase C (PKC), diacylglycerol, mitogen-activated protein kinase (MAPK), and 
phosphoinositide turnover [61–64]. Another proliferative effect of PRL is on the β-cells of 
the pancreas [65,66]. A subsequent in vitro study using the β-cell line INS-1 showed that 
PRL triggers β-cell proliferation via various signal transduction pathways [67]. Moreover, 
PRL has been found to up-regulate ornithine decarboxylase (ODC) in a number of tissues 
including liver, heart, kidney, muscle, adrenal, gonads, and prostate [2,68]. ODC is a rate-
limiting enzyme in polyamine biosynthesis that is classified as a growth mediator due to its 
effects on DNA and RNA synthesis in somatic cells [68]. 
1.4.5 Metabolism 
Several endocrine and metabolic actions of PRL that are not related to reproduction have 
been reported. In adipose tissue, lipogenesis is suppressed by PRL to spare metabolites to the 
mammary gland during lactation [69,70], while another study also reported that low 
physiological PRL doses suppressed lipolysis in adipose tissue of non-lactating rats, 
suggestive of a physiological-status-specific action for PRL [71]. Via activation of signal 
transducer and activator of transcription (STAT) 5, PRL induces peroxisome proliferator-
activated receptor-γ a known regulator of adipocyte differentiation [72,73].  
PRL also regulates the β-cells in the pancreas, where it increases insulin secretion and 
decreases the glucose threshold for insulin secretion [74–76]. This may in turn be connected 
to a metabolic adaptation to the state of pregnancy. PRLR knockout (PRLR-/-) mice develop 
reduced pancreatic islet density and showed a blunted insulin secretory response to glucose 
[77].  
GH has more prominent actions on metabolism compared to PRL. Generally, GH has 
anabolic actions in muscle and bone that involve the stimulation of protein synthesis, while 
its actions in adipose tissue are catabolic [78]. In this tissue, GH promotes lipolysis and break 
down fatty acids instead of glucose, which partly explains its diabetogenic effects including 
hyperglycemia and decreased insulin sensitivity. In the liver, GH reduces glucose uptake and 
promotes gluconeogenesis, glycogenolysis and lipogenesis. Mice with a GHR deletion in the 
β-cells exhibit decreased glucose-stimulated insulin release and decreased β-cell hyperplasia 
in response to high fat diet (HFD), which indicates an important role of GH in β-cell 
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proliferation [79]. 
1.4.6 Inflammation and immunity  
Beside their metabolic functions, PRL and GH also participate in regulating the immune 
system. Different types of immune cells express both PRL and GH, along with their 
respective receptors [80–82]. The function of PRL/GH in modulating the immune system is 
controversial. Studies suggest that GH promotes the production of pro-inflammatory 
cytokines such as interleukin (IL)-1α, IL-6 and tumor necrosis factor α in immune cells [83], 
while other studies demonstrate opposite actions [84]. Poor clinical outcome in patients with 
septic shock is also reported to be associated with high levels of GH [85]. Although GH 
affects immune function, its precise effects and their underlying mechanisms remain to be 
elucidated. 
 
Figure 2. Summary of the different biological actions promoted by GH and PRL. GH has 
more prominent actions on longitudinal bone growth and metabolism, while PRL exerts a 
prominent function on reproductive organs. 
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1.5 INTRACELLULAR SIGNALING PATHWAYS INDUCED BY 
PROLACTIN AND GROWTH HORMONE 
 
1.5.1 JAK-STAT pathway 
Members of the class 1 cytokine family lack intrinsic kinase activity; instead, each receptor is 
bound to a specific tyrosine kinase, i.e. Janus Kinase (JAK). JAK phosphorylation leads to 
phosphorylation and nuclear translocation of STAT proteins. The JAK2-STAT5 pathway is 
the best-known signaling pathway utilized by both GH and PRL. When ligands bind to either 
GHR or PRLR, JAK2 tyrosine kinases bound to two receptor molecules become activated 
[86–88]. Activation of JAK2 promotes phosphorylation of STAT proteins [2,89,90]. A total 
of seven different STAT proteins have been identified in mammals [91]. GHR/PRLR 
signaling is primarily mediated by STAT5 proteins [92,93], but also by STAT1 and STAT3. 
Once STAT proteins are phosphorylated, they dimerize, and subsequently move to the 
nucleus, where they bind a specific DNA sequence, initiating GH/PRL-specific gene 
transcription (Figure 3) [94–96].  
 
Figure 3. The cytokine-triggered JAK-STAT signal transduction pathway. Phosphorylated 
STAT proteins dimerize, and migrate to the nucleus to act as transcription factors, initiating 
transcription of target genes. 
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1.5.2 MAPK pathways 
The JAK-STAT cascade is considered to be the most important signaling pathway evoked by 
cytokine receptors. However, other pathways like the MAPK, or extracellular signal-
regulated kinase (ERK) pathway, is also involved in signal transduction by cytokine 
receptors, and plays an important role in gene transcription, cellular proliferation and 
prevention of apoptosis. The ligand SH2 domain-containing transforming protein (Shc) binds 
to the phosphorylated receptor, and is phosphorylated by JAK2. This activates Shc, which 
subsequently binds to and activates growth factor receptor-bound 2 (Grb2) protein. Grb2 
interacts with Sons Of Sevenless (SOS), and this triggers further signaling by the downstream 
signaling proteins Ras, Raf and MEK. Both GH and PRL have been shown to activate 
MAPK through sequential activation of the Shc/Grb2/SOS/Ras/Raf/MEK/MAPK cascade, 
which then activates ERK 1 and 2 [97–99]. Unlike the STAT signaling pathway, GH/PRL 
activation of the MAPK pathway is independent of JAK2, since deletion of JAK2 has no 
effect on the activation of ERK1 and 2 kinases [100]. However, studies also suggest a cross 
talk between the JAK-STAT and the MAPK cascade pathways [101,102]. The activation of 
the ERK1/2 kinase-signaling cascade results in the phosphorylation of STATs, ribosomal S6 
kinases and many other downstream transcription factors. 
1.5.3 mTOR pathway 
The mammalian target of rapamycin (mTOR) pathway responds to diverse factors including 
energy status, nutrients, amino acids, oxygen, and stress. mTOR is an atypical 
serine/threonine protein kinase that belongs to the phosphoinositide 3 kinase (PI3K)-related 
kinase family [103]; this kinase interacts with several proteins to form two distinct complexes 
named mTOR complex 1 (mTORC1) and 2 (mTORC2) [104]. GH and PRL increase the 
level of protein synthesis in the cell, and AKT-mTOR-S6 kinase is an important signalling 
molecule involved in this effect [105]. PI3K activates the serine/threonine protein kinase 
AKT, which in turn activates mTOR. An important downstream effect of mTORC1 
activation is increased protein synthesis, mediated by S6 kinase. This kinase activates mRNA 
biogenesis and facilitates protein translation [106]. In fact, all of these upstream signals, 
including those activated by growth factor binding, are integrated and transmitted through a 
heterodimer consisting of tuberous sclerosis complex (TSC) 1 and 2, which acts as an 
inhibitor for mTOR. The mTOR pathway kinases, notably AKT and ERK1/2, phosphorylate 
TSC to inactivate it, and thus activate the mTORC1. The mTOR-containing complexes also 
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have different sensitivities to the immune suppressive drug rapamycin, a well-known 
inhibitor of mTOR [107]. An anti-apoptotic function for PRL on rat Nb2 lymphoma cells has 
been reported to occur through activation of the PI3K/Akt pathway [108], and this action of 
PRL is further inhibited by rapamycin (Figure 4) [105].  
 
Figure 4. TSC2 complex is activated through the growth factor-PI3K-AKT signaling 
pathway. Activation of the TSC2 complex overcomes its inhibitory effect on mTOR, and 
constitutively turns on cell growth, proliferation and protein synthesis. 
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1.5.4 IRS and PI3 kinase pathway 
Activation of the Insulin Receptor Substrates (IRSs) and PI3K pathways by insulin and IGF-1 
is well studied. However, GH and PRL are also able to activate IRS-1, -2, -3 through JAK2 
phosphorylation. Phosphorylated IRS proteins also constitute a binding site for the 85 kDa 
regulatory subunit (p85) of PI3K [109], which in turn, once activated, is involved in the 
regulation of glucose uptake into the cell by translocation of glucose transporter type 4 to the 
cell surface. Moreover, DNA synthesis, cell proliferation and cellular apoptosis can be 
induced through IRS phosphorylation evoked by PRL and GH [110,111]. Finally, GH and 
PRL also trigger other signaling pathways, which are out of the scope of this thesis.  
1.6 CONTROL OF PROLACTIN AND GROWTH HORMONE 
SENSITIVITY  
Several hormone systems are characterized by changes in target tissue sensitivity. Key factors 
in hormone sensitivity include the number of cell-surface receptors, and the duration of 
receptor-activated intracellular signals. Many studies have addressed agents that control 
receptor number, and it is also recognized that tight control of receptor number is required to 
regulate the duration of hormone-activated signals. A common theme concerning the latter is 
the inactivation of tyrosine-phosphorylated intracellular proteins by tyrosine phosphatases. 
Alternatively, activated receptor signals can be processed using proteasomal breakdown, as 
described below.  In this work, particular focus is given to two different proteins, SOCS2 and 
TSC2 that uniquely impinge on JAK-STAT and mTOR activation. 
1.6.1 Suppressor of cytokine signalling  
One prerequisite for cells to respond to GH/PRL is the cellular levels of GHRs/PRLRs, and 
one interesting regulator of the levels of GHR, and probably of PRLR, is suppressor of 
cytokine signalling 2 (SOCS2). This protein, which is able to regulate the intracellular 
signalling cascades (JAK-STAT), is essential to avoid the unwanted outcomes of excessive 
hormone stimulation, e.g. over-growth and cancer development. Knockdown of SOCS2 in 
primary cells from animals and humans increases the level of GHR, and this leads to 
increased GH sensitivity.  
The SOCS protein family consists of eight different proteins (SOCS 1-7, and the cytokine 
induced Src-homology2 (SH2) protein [CIS]) [112,113]. All SOCS proteins contain a C-
terminal SOCS-box, a central SH2 domain and an N-terminal domain of varying length. 
  
 
 
13 
These proteins are intracellular regulators of the cellular sensitivity to extracellular ligands. In 
particular, ligands activating cytokine receptors signaling through the JAK-STAT pathway 
have been connected to SOCS. SOCS proteins are the target recognition subunits of 
Culllin2/5-Rbx2 E3 ubiquitin ligase complexes, which transfer ubiquitin to tyrosine-
phosphorylated proteins for degradation either in the lysosomes or proteasomes [114,115]. 
Four members of the SOCS-family have been shown to regulate GHR signaling, i.e. SOCS 1-
3, and CIS, which act in a negative feedback loop to terminate the GH signal [116]. Figure 5 
shows SOCS2 binding to GHR and its mediation of ubiquitination.  
 
Figure 5. SOCS2 binds to the GHR and mediates its ubiquitination. (1) SOCS2 assembles 
an E3 ubiquitin ligase complex together with Elongin B and C, Cullin5 and Rbx2. SOCS2 
then binds to phosphorylated tyrosines on the GHR through its SH2 domain. (2) The GHR is 
poly-ubiquitinated by an E2 conjugating enzyme. (3) The ubiquitinated GHR is degraded by 
the proteasome. 
Experimental elimination of different SOCS proteins demonstrates that individual SOCS 
proteins have distinct functions in the contexts of inflammation, metabolism and growth. 
Elimination of certain SOCS proteins, e.g. SOCS1-3, results in increased inflammatory 
responses [117,118]. In addition, SOCS2 knockout (SOCS2-/-) mice display gigantism 
compared to controls, without elevation of GH [119], a condition explained by increased GH 
sensitivity [120]. These mice are highly sensitive to GH because SOCS2 deficiency leads to a 
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reduced receptor breakdown, and consequently more GHRs [121]. SOCS2 has also been 
implicated in the negative regulation of PRL signaling. Absence of SOCS2 rescues the failure 
in lactation and reduction of mammary STAT5 phosphorylation in PRLR-heterozygous 
knockout mice [122,123]. In contrast to the GH related phenotype observed in SOCS2-/- mice, 
the gigantism in which presumably identifies SOCS2 as a down-regulator of GH function, the 
connection of any phenotype in mice missing a particular SOCS gene to PRL function has 
not yet been found. 
1.6.2 Tuberous sclerosis complex 
As mentioned above, a surge of research has shown that the TSC genes encode proteins that 
suppress the mTOR pathway. Molecular genetics research has identified two TSC genes, 
TSC1 and TSC2, the products of which form heterodimers and work together as one complex 
to control cell growth and proliferation through inhibition of mTOR. Loss of function or 
mutation in the TSC1 or TSC2 genes leads to similar phenotypes, although TSC2 mutations 
are more common [124]. Mutations in either the TSC1 or TSC2 genes cause an autosomal 
dominant genetic disorder known as TSC. This disease is characterized by development of 
multiple benign hamartomas in multiple organ systems [125]. Another abnormal phenotype 
associated with mutations in TSC2, which in turn results in dysregulated cell growth, is 
observed in lymphangioleiomyomatosis (LAM) disease [126–128]. LAM is a rare disease 
affecting females of reproductive age, and is characterized by an uncontrolled proliferation of 
lung LAM lesions consisting of smooth muscle cells, leading to pulmonary insufficiency and 
subsequent death if not treated [127]. Here we speculate that loss of the TSC2 gene’s 
inhibitory action on mTOR may stimulate PRL synthesis and increase a cell’s sensitivity 
level to PRL. 
1.7 PATHOLOGICAL CORRELATES TO PROLACTIN AND 
GROWTH HORMONE 
Endocrine disorders can be put into categories such as over-production or under-production 
of hormones, as well as in changes in hormone sensitivity. In the case of GH/PRL, all of 
these scenarios exist. Over the years, different pharmaceuticals have been developed to 
manage such conditions (Figure 6). 
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Figure 6. Different pathological conditions associated with GH/PRL. There is no disease 
yet identified which involves insensitivity to PRL. 
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1.7.1 Conditions associated with a disturbed prolactin and growth hormone axis  
In humans and animals, excess amounts of GH lead to gigantism or acromegaly, depending 
upon when during life the hypersecretion begins. The term acromegaly was first coined in 
1886 by Pierre Marie [129] to describe a condition caused by increased GH levels that appear 
after fusion of the epiphyseal plate at puberty [130]. More than 95% of patients with 
acromegaly harbour a GH-secreting pituitary tumor, which is clinically presented as an 
enlargement of extremities, prognathism and macroglossia [131]. Such patients are at a high 
risk to develop co-morbidities related to elevated GH levels, e.g. diabetes and cardiovascular 
disease [132]. 
Deficiency of GH leads to dwarfism, and such patients can be treated with exogenous GH 
treatment [133,134]. A particular form of dwarfism, i.e. Laron dwarfism, is caused by 
mutations in the GHR leading to complete GH insensitivity. People with Laron syndrome 
have mutations in the extracellular domain of GHR, commonly high levels of GH 
concomitant with low levels of IGF-1, and do not respond to exogenous GH treatment 
[135,136]. Besides Laron syndrome, other types of acquired insensitivity to GH exist, e.g. in 
kidney disorders and during glucocorticoid treatment [137,138]. 
Regarding the GH insensitivity in the Laron syndrome, there are no known genetic diseases 
associated with mutations in the genes coding for either PRL or PRLR in humans [139]. 
Beside PRL overproduction due to prolactinoma, a variety of other causes of 
hyperprolactinemia in humans have to be ruled out due to conditions such as psychotropic 
drug use, stress, chronic renal failure and some tumors [140,141]. The main clinical 
manifestation associated with elevated levels of PRL, in both sexes, is reproductive 
dysfunction resulting in hypogonadism, infertility and galactorrhea [142,143]. Moreover, 
insensitivity to PRL is not yet clinically known. 
1.7.2 Growth hormone and prolactin role in cancer 
There are many different causes of cancer including infection, chemical exposure, genetic 
mutations and local cytokine production. The hallmarks of cancer are self-sufficient growth 
signals, unlimited proliferation, permanent angiogenesis, failure of apoptotic mechanisms and 
insensitivity to anti-growth signals. One phenomenon in cancer cells is “the Warburg effect”, 
in which cancer cells favor the use of aerobic glycolysis, in preference to mitochondrial 
  
 
 
17 
oxidative phosphorylation that is used by normal cells to generate adenosine 5′-triphosphate 
[144,145]. The significance of cell metabolism in cancer is also suggested by findings that the 
drug metformin, a widely used drug for the treatment of type 2 diabetes, can protect from 
cancer. The anti-neoplastic effect of metformin remains elusive, although studies demonstrate 
a variety of mechanisms including attenuation of the Warburg effect [146]. In this context, 
researches have shown that metformin decreases the levels of circulating hormones such as 
androgens and estrogen that are known to be linked with postmenopausal breast cancer 
development [147–149]. 
Many human cancers develop as a result of exposure to viral infection. The most common 
one is human papillomavirus (HPV) infection, specifically by HPV-16 and -18, which 
contributes to a high risk of cervical cancer [150,151]. In this context, clinical screening 
programs for cervical cancer, i.e. tests for HPV, have been introduced in some countries. A 
new line of research in the last years suggest that human cytomegalovirus (CMV) infection 
can also contribute to several human malignancies including breast, colon, prostate, 
rhabdomyosarcoma, hepatocellular cancer, salivary gland tumors, neuroblastoma, and brain 
tumors [152]. In searching for treatments of malignancies, one way to control cell 
proliferation and transformation might be through the introduction of tumor suppressor genes 
into the cancer cell. One of the most commonly mutated tumor suppressor genes in humans is 
p53, a gene which is involved in almost 50% of all cancers, especially those of the lung, 
breast, ovary, colon, bladder and prostate [153]. 
Since hormones regulate cell growth and differentiation, they also have a role in cancer 
development. In fact, many tumors respond therapeutically to agents interfering with 
hormone action [154]. The influence of GH/PRL on different forms of cancers in humans has 
been widely discussed, and the realization that GH/PRL also have paracrine/autocrine actions 
is highly relevant in this context. 
GH/IGF-1 act as potent proliferative agents, and IGF-1 is also a well known mitogen with 
anti-apoptotic effects that seem to contribute to the development of neoplastic lesions in 
colorectal tumor development [155]. It is interesting to note that loss of GHR creates an 
unfavorable situation for tumor growth both in animals and humans [156,157]. 
Overproduction of PRL has been reported to increase the aggression of colorectal cancer in 
humans [158], and to contribute to the pathogenesis and progression of human breast cancer 
[159]. Animal data suggest that PRL increases the rate of tumor cell growth and metastasis 
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[160]. Contradictory findings, however, also suggest that PRL has a favorable role in breast 
cancer prognosis [161]. Local production of PRL in myometrial smooth muscle tumors 
(uterine leiomyomas) indicates that the mitogenic activity of PRL participates in the 
progression of such tumors [162]. It has been suggested that PRL might be involved in the 
progression of LAM disease (see below), since only females are affected and because the 
disease is aggravated during pregnancy – a condition associated with elevation of lactogenic 
hormones [163]. In human ovarian cancer cells, studies also showed that lower levels of 
tumoral PRL/PRLR in clinical samples were associated with longer patient survival, 
suggestive of an important role for PRLR in the pathogenesis of such tumours [164]. 
GH/PRL hypersensitivity is suspected in many tumors, e.g. in prostate cancer, since clinical 
studies reported increased levels of PRL in this cancer [165]. Furthermore, an increased 
expression of PRLR was demonstrated in dysplastic lesions of human prostate, as well as in 
low grade cancer, compared with normal tissues [166]. GH is also known to play a role in the 
normal physiology of the prostate gland, in addition to androgens, the main regulator of 
prostate function [167]. GHR mRNA levels were reported to be significantly higher in 
prostate carcinoma tissues, compared to benign prostate hyperplasia and normal tissues [168]. 
In summary, several studies suggest a potential role for PRL and/or GH hypersensitivity in 
different pathophysiological states related to tumor growth.  
1.8 PROLIFERATIVE CONDITIONS ASSOCIATED WITH 
INCREASED SENSITIVITY TO GROWTH HORMONE AND 
PROLACTIN  
GH and PRL also play roles in metabolism, regeneration and proliferation, and it is 
reasonable to believe that tissue sensitivity to GH/PRL might be important in this context. 
This project has investigated three different conditions, i.e. LAM, glioblastoma brain tumors 
and diabetes mellitus, to the relevance of GH/PRL tissue sensitivity in these disorders. 
1.8.1 LAM  
LAM is a multisystem disease, which affects almost exclusively women of childbearing age. 
It is manifested as pulmonary cystic destruction [126,169], and can be associated with extra-
pulmonary tumour lesions, e.g. angiomyolipomas [170]. The disease affects the lungs, and 
results from uncontrolled proliferation of smooth muscle cells and melanocytes, which in turn 
infiltrate into the surrounding tissues and lead to airway obstruction [171]. Positive reaction 
to human melanin black antibody (HMB-45) is diagnostic of LAM [172]. Interestingly, a 
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potential biomarker for LAM is increments in serum vascular endothelial growth factor D 
(VEGF-D) [173,174]. The disease can occur as sporadic cases, or can be associated with an 
inherited autosomal dominant disorder (TSC), but in both cases is caused by mutations in the 
TSC1/TSC2 genes, although TSC2 mutations are more common [128,175]. The protein 
products of the TSC genes, Hamartin and Tuberin, together inhibit the mTOR signaling 
pathway, a major regulator of cell size and proliferation [176]. In LAM, mutations in TSC2 
lead to mTORC1 activation and further phosphorylation of the downstream kinases which 
regulate cell growth and proliferation [176]. Until recently, LAM tumors were considered 
benign, but evidence for their neoplastic nature, e.g. invasiveness and metastasis, has 
accumulated. Similar TSC2 mutations from the same patient were detected in micro-dissected 
pulmonary LAM and in angiomyolipoma cells but not in normal cells, suggesting a common 
origin for both types of cells [177]. Moreover, recurrent LAM cells after lung transplantation 
share the same TSC2 mutations as those in native LAM cells, indicating that LAM cells can 
migrate and metastasize in vivo to the transplanted lungs [178]. The uterine or pelvic cavity 
organs have been proposed as the primary site of origin of LAM [179]. 
Clinical trials with inhibitors targeting mTORC, e.g. rapamycin (clinically known as 
Sirolimus) demonstrate a decrease in tumor progression and improved pulmonary function, in 
LAM patients [180–182]. Despite clinical improvements resulting from Sirolimus treatment 
in LAM patients, this treatment can cause serious adverse reactions. For this reason, patients 
need to be closely monitored; the current belief is that Sirolimus treatment only halts the 
progression of the disease and is not a cure [180]. Endocrine components of LAM have been 
suspected, because females are predominantly affected, and because the disease is aggravated 
during pregnancy – a condition associated with elevations of PRL. This is further supported 
by one previous study demonstrating that LAM lesions produce PRL, and showing that 
patients with LAM have elevated serum PRL levels [163]. Study II included in this thesis 
hypothesizes that LAM lesions are hypersensitive to PRL, which might be of relevance for an 
understanding of factors that regulate their growth. The scientific progress in LAM research 
is summarised in figure 7. 
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Figure 7. Historical representation of the scientific progress in LAM research. 
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1.8.2 Glioblastoma Multiforme (GBM)  
GBM is the most common and aggressive primary brain tumor in humans, accounting for 
approximately 12-15% of all intracranial tumors, with a median survival of 15 months despite 
advanced cytotoxic therapy including surgical intervention [183]. Angiogenesis (the process 
of forming new vessels) is essential for tumor growth and metastasis. One main feature 
characterizing GBM is neovascularization, i.e. an imbalance between pro-, and anti- 
angiogenic factors [184,185].  A number of different alterations of cell signaling molecules 
have been found to promote angiogenesis in GBM, exemplified by increased signaling from 
VEGF receptors (VEGFRs), epidermal growth factor receptor (EGFR) [186] and platelet–
derived growth factor [184]. On a genetic level, primary GBM is characterized by deletion or 
mutations of the tumor suppressors INK4a, p53 and phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) [187,188]. 
SOCS2 and TSC2 are intracellular proteins that regulate the JAK-STAT and mTOR 
pathways respectively. Previous experimental and clinical studies have reported increased 
STAT and mTOR activity in GBM [189–193]. Studies of SOCS/TSC expression in brain 
tumors have shown that SOCS1 and SOCS3 are apparently expressed in GBM and play a 
significant role in tumor pathogenesis [194]. Of note, mTORC1 hyper-activation due to loss 
of TSC1 is not sufficient for gliomagenesis to develop but it accelerates malignant 
gliomagenesis when it is combined with oncogenic signals [195]. Patients with TSC have bi-
allelic loss of TSC1/TSC2, and a few clinical cases have been reported the occurrence of 
GBM in such patients [196]. The limited success in the use of EGFR inhibitors to treat 
recurrent GBM opens the gates for new treatments such as combination therapy that also 
inhibit the mTOR pathway through PI3K.   
With regard to PRL, it has been suggested that initiation and cessation of vascularization in 
the mouse placenta correlates with the sequential expression of proliferin and proliferin-
related peptide [197,198]. These non-classical members of the PRL/GH family have been 
shown to act in an autocrine/paracrine fashion to either stimulate or inhibit various stages of 
angiogenesis. It is, however, interesting to note that anti-angiogenic factors induce local 
production of PRL, as a pro-survival response. A recent study showed that the combined 
application of the angiogenic inhibitors endostatin and tumastatin up-regulates the PRLR in 
GBM in vivo, and that the activation of PRLR signaling stimulates proliferation of tumor 
cells [199]. All of these observations suggest an important rule of PRL and its receptor in the 
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pathogenesis of GBM, and the targeting of this receptor (our study aim) may offer a new 
therapeutic approach in the field of GBM brain tumors. 
1.8.3 Diabetes Mellitus 
Diabetes mellitus (DM) is considered to be one of the most challenging diseases and health 
burdens to humans in the 21st century [200]. In general, there are two types of DM: Type 1 
and Type 2 diabetes mellitus (T1D and T2D) that in common have the feature of high blood 
glucose levels that can cause serious health complications. T1D is caused by the destruction 
of the insulin-producing beta cells in the pancreas, while in T2D, the body is resistant to 
insulin, and this eventually leads to impaired insulin production by exhausted β-cells 
[201,202]. Accumulated data from different studies indicates a pivotal role for the β-cell mass 
in the pathogenesis of diabetes. β-cell growth, proliferation and differentiation, along with the 
regulation of insulin secretion, are influenced by different growth factors including GH, IGF-
1 and PRL [203,204]. The best known states of increased β-cell mass are obesity [205,206] 
and pregnancy [207], as represented in Figure 8.  
It is relevant to note that β-cells express GHRs/PRLRs [208,209], and that increased β-cell 
mass observed during pregnancy is suggested to be caused by the increased secretion of 
placental and pituitary hormones targeting such receptors [66,203,209]. This adaptive 
response of β-cells in pregnancy is associated with elevated levels of GH, PRL and placental 
lactogen [210,211], and is possibly linked to pathways of increased tissue sensitivity to these 
hormones. As mentioned before, DM can be a consequence of increased circulating GH 
levels, referred to as the diabetogenic effect of GH [60]. In relation to SOCS2, GH-associated 
diabetic features are not observed in SOCS2-/- mice under standard diet (hypersensitivity to 
GH). Yet GH levels are lower in SOCS2-/- mice, despite similar IGF-1 levels in SOCS2-/- 
mice and their wild-type (WT) littermates, indicating higher GH sensitivity in SOCS2-/- mice 
[212], and suggesting unique actions of SOCS2 in the regulation of glucose metabolism. 
Given the fact that SOCS2 also modulates inflammatory pathways [213], it is unknown 
whether its regulatory actions in the pancreas also impact on β-cell survival in models of T1D 
[214]. Important roles for other SOCS proteins in diabetes have been suggested, these 
intracellular regulators affect key pathways of relevance for diabetes development [215]. For 
example, it has been shown that elimination of SOCS1 increases the interferon response and 
potentiates islet cell death [216]. Furthermore, SOCS3 potently protects against T1D through 
suppressed production of IL-1β and TNF-β in pancreatic β-cells [217,218]. 
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Changes in tissue sensitivity to other hormones like insulin that is involved in the 
development of diabetes have been reported after viral infection. Human adenovirus-36 
infection has been associated with a lower occurrence of T2D and better insulin sensitivity, as 
reflected by reduced Homeostatic model assessment and insulin resistance (HOMA-IR) and 
increased levels of insulin-like growth factor binding protein-1 [219]. 
 
 
 
Figure 8. A model of β-cell expansion in response to increased metabolic loads. (A) β-cells 
normally undergo very little turnover in adult life. Some physiological states like pregnancy 
and obesity stimulate β-cell proliferation in response to an increased systemic demand for 
insulin. (B) To accomplish this state, both proliferative and survival pathways are activated 
in β-cells, protecting against the onset of diabetes. (C) Failure of the β-cell mass expansion 
response to metabolic demands and continued β-cell apoptosis overcomes β-cell renewal 
mechanisms and leads to diabetes. Adopted from [207]. 
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1.9 DEVELOPMENT OF DRUGS ACTING ON THE GROWTH 
HORMONE AND PROLACTIN AXIS 
 
There are several different pharmaceuticals that can affect the GH or PRL axis. In principal, 
these drugs are used to influence secretion, serve as hormone replacements or as receptor 
blockers. In this thesis, a particular emphasis is placed on PRLR antagonists. 
1.9.1 PRLR antagonist development 
As described in Figure 6, there are several compounds that target the GH/PRL system, with 
the exception of a PRLR antagonist (PRLRA). The development of a PRLRA (not yet in 
clinical use) is described below. The different utilities of such an antagonist can be 
considered since PRL production is not solely restricted to the pituitary gland, but also occurs 
in extra-pituitary tissues, e.g. the mammary gland, prostate and lymphocytes. Locally-
produced PRL can take part in proliferation and in tumor development [159,220–223]. One 
may note that dopamine receptor agonists are clinically used as anti-PRL drugs. These drugs 
reduce production of PRL from the pituitary, but cannot target extra-pituitary PRL 
production.  
Recently, a GHR antagonist has been developed by replacing a glycine at position 120 for an 
arginine; this interferes with the binding site of GH to its receptor [224,225]. This antagonist 
is used clinically under the name Pegvisomant® for the treatment of acromegaly [226]. This 
has stimulated efforts to develop PRLRA, based on a similar principle (Figure 9). 
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Figure 9. Development of a PRLRA that antagonizes PRL’s action at the cellular level. 
Dopamine agonists affect pituitary PRL production only, but have no role on local PRL 
production and actions in other body organs. 
1.9.2 Low-affinity PRLRA 
PRL interacts through two binding sites (BS1 and BS2) with receptor dimer molecules and 
forms the PRL-PRLR homodimer [43,227]. In human PRL, 13 residues are involved in the 
process of receptor binding. Based on the two site-binding mechanism illustrated in (Figures 
1 and 10), the first generation PRLRA were designed to impair BS2 [228]. By substituting 
glycine at position 129 in the conserved helix 3 for arginine, antagonists were created and 
named G129R-hPRL [229]. Multiple in vitro and in vivo assays proved the antagonistic 
activity of G129R-hPRL, but partial agonistic activity was also detected [230]. This 
stimulated efforts to develop a second-generation PRLRA by introducing N-terminal 
deletions (Δ1–9-G129R-PRL and Δ1–14-G129R-PRL) into the PRL sequence. Although this 
resulted in a pure antagonist, high concentrations were needed (>10-fold molar excess) to 
compete with endogenous PRL [231,232]. Other PRLRA variants have been reported, but 
they also have the drawback of residual agonist activity [232,233]. 
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Figure 10. Models of PRLRA binding to PRLR. Model 1 represents the old theory, in which 
PRLRA competes with PRL and binds to PRLR, preventing receptor dimerization. In model 2, 
PRLRA competes with PRL and binds to a pre-dimerized receptor. Adopted from [234]. 
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1.9.3 High-affinity PRLRA 
It is clear that high receptor affinity is essential to generate a potent in vivo PRLRA. Different 
screening techniques have been used to identify amino acid changes in G129R-hPRL to 
increase the binding to BS1. A successful strategy to generate antagonists with significantly 
improved affinity to block the receptor has identified a series of single mutation sites, which 
enhanced BS1 affinity. By combining the single mutations, researchers succeeded in 
generating an antagonist with significantly improved affinity to block the receptor. We have 
used this antagonist, PRL-S33A, Q73L, G129R, K190R in our study [235,236]. 
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2 AIMS 
Factors controlling hormone sensitivity are an important aspect of several types of disorders. 
Regulators of GH and PRL sensitivity may be related to both metabolic and hyper-
proliferative disorders. In this thesis, we hypothesize that SOCS2 and TSC2 uniquely 
impinge on JAK-STAT activation and on mTOR activation, and that this in turn regulates the 
cellular level of GH and PRL receptors. We also hypothesize that a PRLRA could offer a 
new therapeutic approach in the field of tumor treatment by blocking localized actions of 
PRL in cases of PRL hypersensitivity restricted to a particular organ site.  
 
The present study had the following aims: 
1. To experimentally investigate relationships between SOCS2 and diabetes.  
 
2. To demostrate if increased GH/PRL sensitivity in SOCS2-/- mice will have any impact 
on β-cells. 
 
3. To investigate if the mTOR suppressor TSC2 participates to regulate components of 
the PRL/GH system. 
 
4. To evaluate the activity of a PRLRA in PRL-sensitive tumor cells. 
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3 MATERIAL AND METHODS 
This section provides a brief summary of the major methods used in this thesis. For more 
detailed methodological descriptions, please refer to the individual papers. 
3.1 MATERIALS 
3.1.1 Animals 
In Paper I, we have used the SOCS2-/- mice (C57BL/6J), as previously described [212]; 
littermates WT mice were used as controls.  
3.1.2 Cell lines 
All cells were obtained from the American Type Culture Collection, except for the human 
LAM/TSC cells, which were isolated from human LAM lesions. Before stimulation with 
PRL or GH, cells were washed and incubated overnight in medium lacking fetal bovine 
serum (FBS). 
CRL-2620 cells were used to study the effects of WT and mutant versions of TSC2 on the 
PRLR and GHR (Paper II). CRL-2620 cells originating from a TSC2-/+ mouse sarcoma were 
cultivated in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS 
(Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C, 5% CO2. Superfect 
(Qiagen) was employed according to the manufacturer’s protocol to carry out transfections. 
LAM/TSC cells (used in paper II) were previously characterized as a homogenous 
population of α-smooth muscle-like cells. These cells have absence of TSC2 protein product 
for a TSC2 mutation of one allele and an epigenetic alteration of the second allele [175]. The 
cells were used to study the effects of TSC2 mutations on PRLR, and were grown in a 50/50 
mixture of DMEM/Ham F12 (Gibco) supplemented with hydrocortisone (2.5 µg/ml), EGF 
(10 ng/ml), sodium selenite (8.6 ng/ml), insulin (25 µg/ml), transferrin 10 ug/ml), ferrous 
sulphate (0.445 µg/ml) and 15% FBS. 
U251-MG cells were used in Study III to evaluate the activity of a PRLRA in PRL sensitive 
tumor cells. Cells were cultivated in DMEM supplemented with 10% FBS, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37°C, 5% CO2. 
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3.2 METHODS 
3.2.1 Multiple low-dose streptozotocin model 
We investigate the role of SOCS2 on DM induced by multiple low-dose streptozotocin 
(MLDSTZ) (Paper I). We used the MLDSTZ model to induce T1D in SOCS2-/- and WT 
littermates. Sixty-five days after MLDSTZ treatment was stopped, mice were sacrificed and 
tissues were collected for further studies.  
 
Figure 11. Schematic representation for MLDSTZ treatment in SOCS2-/- and WT mice that 
were used as a model of autoimmune diabetes and β-cell destruction in vivo. 
 
3.2.2 Assessment of whole body insulin sensitivity  
Insulin sensitivity (Paper I) was assessed in vivo by measurement of fasting blood glucose, 
fasting plasma insulin, intraperitoneal glucose tolerance tests (ipGTTs), intraperitoneal 
insulin tolerance tests (ipITTs), and HOMA-IR. Plasma insulin levels were measured using 
commercial ELISA kits. Blood glucose levels were measured using a glucometer (Roche 
Diagnostics, Basel, Switzerland).  
3.2.3 Measurement of pancreatic insulin  
To assess pancreatic insulin content (Paper I), one third of the pancreas mass from the tail 
was digested and homogenized in 1 mL acidic ethanol (70% ethanol and 37% HCl) for 
insulin quantification per unit weight pancreas. Insulin was determined using an ultrasensitive 
rat insulin ELISA kit (Crystal Chem, IL, USA). We also analyzed pancreatic insulin content 
before and after MLDSTZ treatment by immunohistochemistry (IHC). 
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3.2.3.1 Isolation of pancreatic islets 
Islets of Langerhans were isolated from SOCS2-/- and WT control mice by collagenase 
digestion in Hank’s balanced salt solution, followed by sedimentation, as described [237]. 
Islets were selected under stereomicroscope, and cultured free-floating in RPMI-1640 with 2 
mmol/L glutamine, 10% (v/v) FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 11 
mmol/L glucose. Lipotoxicity was induced by using 250 µM palmitate and hormonal 
treatment carried out as specified in paper I. Secreted insulin and islet insulin content were 
analyzed by RIA using 125I-labeled insulin and anti-porcine insulin, generated at the 
Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden. 
3.2.4 Western blot 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate denatured protein samples, which were then transferred to polyvinylidene fluoride 
(PVDF) membranes and probed by antibodies to determine the presence and amount of 
proteins of interest (Paper I – III). 
Western blotting is a robust and commonly used technique for the detection and 
quantification of proteins from various types of samples. It involves electrophoretic gel 
separation of the proteins in the sample, followed by transfer to a membrane, blocking and 
then probing with antibodies directed at specific proteins of interest [238,239]. 
3.2.5 Immunohistochemical analysis of PRLR expression  
Immunohistochemistry (IHC) is a powerful method for localizing specific antigens in 
formalin-fixed, paraffin-embedded tissues. IHC is a commonly used technique that is based 
on an antigen–antibody interaction in various types of tissues; it contributes to the diagnoses 
of different diseases, and also differentiates several types of cancer. 
Briefly, tissue sections were de-waxed in xylene and rehydrated in alcohol series, followed by 
blocking the endogenous peroxidase activity. Then tissue sections were stained with 
antibodies, and a colorimetric determination was performed with a three-step horseradish 
peroxidase detection system and the chromogen diaminobenzidine (DAB) (Papers II-III). 
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3.2.6 Assessment of cell proliferation  
In Studies II and III, cells were seeded into 96-well culture plates at a density of 1000 cells 
per 200-µL well and allowed to attach. Then medium was replaced and cells were grown in 
low or high serum and exposed to different treatments. Then cells were ﬁxed by 4% 
paraformaldehyde solution. Relative cell numbers were assessed after 72 h using the 
colorimetric crystal violet assay, in which the bound dye was dissolved with 1% (w/v) SDS, 
and the optical densities (OD) of the extracts were measured at λ= 600 nm.  
3.2.7 PRLRA production and purification  
All steps in the production and purification of PRLRA have been carried out by our 
collaborators in the Royal Institute of Technology, Alba Nova University Center, Dept. of 
Biotechnology, Stockholm, Sweden. 
3.2.7.1 Production of prolactin constructs 
The DNA of three PRL constructs was synthesized and inserted into pET vectors: 
1.Human PRL: M-GSS- LPIC…PRL…NNNC-STOP. 
2.Human PRLRA: M-GSS-RSQV…PRLRA*…NNNC-STOP. This is used in our Studies 
II and III included in this thesis. 
3.Albumin-binding human PRLRA (ABD-PRLRA): M-GSS-ABD-RSQV…PRLRA 
…NNNC-STOP.  
*PRLRA: RCQV….PRL (Δ1-9, S33A, Q73L, G129R, K190R)….NNNC 
3.2.7.2 Protein extraction from inclusion bodies 
High-level expression of PRL recombinant proteins in Escherichia coli (E.coli) leads to the 
formation of highly aggregated protein in what are commonly referred to as inclusion 
bodies. Inclusion bodies are normally formed in the cytoplasm; however, if a secretion 
vector is used, they can form in the peri-plasmic space. Inclusion bodies can be recovered 
from cell lysates by low speed centrifugation. In this study, E. coli BL21 was used for 
expression of the PRL constructs mentioned above, according to the protocol previously 
described [240]. After that, samples were loaded and run on SDS-PAGE gels (Figure 12). 
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                     Figure 12. Extracted PRL constructs evaluated by SDS-PAGE gels.    
               
3.2.7.3 Protein purification by ion exchange chromatography 
Q-Sepharose Fast Flow resin was used for anion exchange purification of the three PRL 
proteins obtained above, using an ion exchange chromatography protocol. PRL, PRLRA and 
ABD-PRLRA were eluted in first elution peak, and 5 ml volumes were collected for each 
protein with OD280=0.07, OD280=0.06 and OD280=0.1, respectively. After concentration, the 
three constructs were loaded on SDS-PAGE gels and pure protein obtained (Figure 13). 
 
Figure 13. Pure proteins obtained and loaded on an SDS-PAGE gel. Lanes 1: ABD-PRLRA 
(27.861 kDa), Lane 2: PRLRA (22.698 kDa), Lane 3: PRL (23.398 kDa).  
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3.2.7.4 PRL construct binding affinity against PRLR  
The interaction and binding affinity between human PRLR and murine serum albumin 
(MSA) and the purified constructs were measured using Biacore SPR Technology 3000 (GE 
Healthcare). PRLR and MSA were immobilized on separate flow cells on a CM5 chip at pH 
4.6 in sodium acetate buffer. The immobilization level was approximately 300RU for PRLR 
and 600RU for MSA. A reference flow cell was created at the same time by activation and 
deactivation. HBS buffer was used for running the analysis and sample dilution, and the 
temperature was set at 25°C. 15 mM HCL was used for chip regeneration. Figure 14 shows 
that all three proteins bind to PRLR and that PRLRA used in this thesis has a 2x affinity to 
PRLR, compared to PRL. 
 
Figure 14. Biacore SPR Technology test. ABD-PRLRA, PRLRA & PRL can bind to PRLR. 
100 nM albumin binds PRLRA and shows the highest binding affinity. Human PRLR was 
immobilized on a biosensor chip in a Biacore 3000 instrument. The obtained curves fitted 
well to a 1:1 Langmuir interaction. 
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3.2.8 Statistical analysis 
In Study I, 2-way ANOVA was performed to test for significant differences in the multiple 
effects of different time points among the 4 mouse groups in each experiment. Student’s t-test 
was used to test for significant differences between two groups. Cell culture experiments in 
all of the studies were performed in duplicates or triplicates in at least three independent 
experiments. Statistical significance of the differences was evaluated using unpaired, 2-tailed 
Student’s t-test and ANOVA tests with post-hoc analysis, and was considered significant 
when the significance level of the test was p < 0.05. 
3.2.9 Ethical considerations  
All animal experiments were approved and carried out in strict accordance with the 
recommendations by the regional ethics committees. Animal experiments were held both at 
the animal facilities at the University of Las Palmas of Gran Canarias, Canary Islands, Spain, 
and at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet, 
Sweden. 
All cell lines obtained from American Type Culture Collection, and the brain tissue 
microarray, were provided from the company with the respective ethical statements. Human 
samples used in the LAM study were obtained from LAM patients who had given written 
informed consent according to the Declaration of Helsinki, and the study was approved by 
the Institutional Review Board of Milan’s San Paolo Hospital. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
SOCS2 deletion protects against multiple low-dose streptozotocin-induced type 1 
diabetes in adult male mice 
In vitro and in vivo studies had showed that SOCS family proteins are relevant to the 
pathogenesis of DM. SOCS2 has been linked to metabolism and diabetes [215], although no 
clear metabolic phenotype has been described to date in SOCS2-/- mice. SOCS2 expression 
has been demonstrated in human pancreatic islets [241]. This prompted us to investigate more 
closely the metabolic phenotype of SOCS2-/- mice to investigate how SOCS2 ablation may 
influence the development of diabetes in a mouse model of autoimmune diabetes and β-cell 
destruction [242]. Our results demonstrate that, compared to controls, 6 month-old MLDSTZ-
induced diabetic SOCS2-/- mice are less prone to develop diabetes (Figure 15).  
 
Figure 15. MLDSTZ induces diabetes in 6-month-old SOCS2+/+ (WT) and SOCS2-/- male 
mice. Blood glucose was recorded every 3-4 days, starting on day 9 after the first STZ 
injection. 
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In MLDSTZ-treated WT mice, there was a clear reduction in the levels of serum insulin 
which was not observed in the SOCS2-/- mouse group (Figure 16A). In MLDSTZ-treated WT 
mice, there was an 88% reduction in pancreatic insulin content, whereas the corresponding 
change in pancreatic tissue from MLDSTZ-treated SOCS2-/- mice only was 20% (Figure 
16B). Along with the analysis of pancreatic insulin content, analyses of pancreatic tissue 
obtained post-treatment showed significantly increased staining for insulin in MLDSTZ-
treated SOCS2-/- mice, compared to control mice (Figure 16C). Therefore, 6 month-old 
SOCS2-/- mice appear partly to be protected from β-cell damage inflicted by MLDSTZ 
treatment. In line with the above findings, more marked glucose intolerance was seen in 
MLDSTZ-treated control mice compared to SOCS2-/- mice, confirming the greater severity of 
diabetes in the former group.  
 
Figure 16. SOCS2-/- mice are partly protected from MLDSTZ-induced damage in β-cells. 
(A) Insulin was measured after overnight fasting. (B) Insulin content per 100 mg of pancreas 
tissue. (C) Insulin fluorescence IHC in the pancreas showed that SOCS2-/- mice are protected 
against MLDSTZ-induced damage in β-cells. Green corresponds to insulin staining, blue 
corresponds to DAPI staining. 
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One possible explanation for this observation might be due to the fact that SOCS2-/- mice are 
highly sensitive to GH and PRL. SOCS2 deficiency leads to reduced receptor degradation, 
and subsequently increased expression of GHR and PRLR [243]. The results from the 
immunostaining of pancreatic sections for GHR and PRLR obtained from both experimental 
groups support the proposed hypothesis that GHR and PRLR protein content are augmented 
in the mouse SOCS2-/- pancreas, compared to control mice (Figure 17).  
 
Figure 17. Immunohistochemical analyses of GHR in the pancreata from WT and  
SOCS2-/- mice. 
Higher pancreatic GHR and PRLR content, in absence of SOCS2, leads to enhanced 
GH/PRL-induced JAK2/STAT5 signaling. Our study showed that both GH and PRL 
increased STAT5 protein expression to a greater extent in the pancreatic tissue of SOCS2-/- 
mice, compared to controls. We also analyzed STAT5 protein activation in isolated islets 
from control mice after treatment with ovine PRL or bovine GH, and both cytokines induced 
STAT5 activation in isolated islets. Other signaling pathways can also be affected by SOCS2 
deficiency. However, the gigantism that has been observed in SOCS2-/- mice is not observed in 
other mouse models of SOCS inactivation, and therefore SOCS2 appears to be a key negative 
regulator of GHR signaling in vivo. In agreement with this, overgrowth in SOCS2-/- mice was 
attenuated in double SOCS2/STAT5b knockout mice, and in SOCS2-/- mice crossed with 
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GHRH signaling-deficient mice [244,245]. This further confirms that increased growth 
observed in SOCS2-/- mice is due to increased sensitivity to GH.  
In line with our results, previous reports have shown that pancreatic β-cell growth, survival 
and insulin production are stimulated by GH through GHR/JAK2/STAT5b activation [246–
248]. Furthermore, in our study, an increase in pancreatic islet size in SOCS2-/- mice was 
demonstrated vs. control mice. A physiological increase in β-cell mass is seen in pregnancy 
[249,250], and this is likely caused by the elevation of placental and pituitary hormones 
targeting GHR and PRLR [211]. Subsequently, SOCS2-/- mice, which possess a higher 
sensitivity to GH and PRL, may display similarities to the pregnant state in terms of β-cell 
function. Thus, our findings of augmented pancreatic GHR/PRLR levels in SOCS2-/- may 
explain the increase in β-cell size and insulin production observed in pancreata from the 
SOCS2-/- mice, in comparison with control mice.  
Another possible explanation for the higher insulin levels observed in SOCS2-/- mice is that 
SOCS2-/- pancreatic islets are more resistant to the damage induced by MLDSTZ. It has been 
shown that PRL injections reduce the severity of STZ in mice [251], whilst other studies have 
demonstrated the ability of activated STAT5 to protect β-cells from various insults, including 
STZ and lipotoxins [252]. Our finding of increased STAT5 activity in SOCS2-/- pancreatic 
islets suggests that GH-, or PRL-mediated activation of STAT5 may protect pancreatic islets 
from the negative effects of MLDSZT-induced diabetes. Our findings are also in line with 
several other reports demonstrating the negative role for SOCS2 in insulin secretion, e.g. 
constitutive activation of SOCS2 in mouse or rat islets, or adenoviral-mediated 
overexpression of SOCS2 in MIN6 cells, all of which lead to decreased glucose-stimulated 
insulin secretion [253]. GH and IGF-I treatment augments β-cell growth and anti-apoptosis, 
both of which could be the ultimate manifestations of a synergistic activation of STAT5 and 
AKT in β-cells [254]. These findings support our hypothesis that increased GH and PRL 
sensitivity in SOCS2-/- mice is likely to explain the reduced damage caused by MLDSTZ.  
GH excess can also affect insulin sensitivity, and may therefore be associated with the 
development of T2D. However, SOCS2 deletion generates a phenotype of increased GH 
sensitivity that is not identical to that due to GH overproduction [255]. Recently, we studied 
hepatic insulin resistance in SOCS2-/- mice and found that a normal control diet did not 
provoke glucose intolerance or insulin resistance in SOCS2-/- mice, whereas HFD caused a 
severe form of insulin resistance [256]. This suggests that the counteracting insulin actions of 
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GH are exacerbated by HFD-related mechanisms (e.g. insulin resistance) under SOCS2 
control. 
In this thesis, along with other regulators of GH and PRL sensitivity, we found two factors 
that might be involved in the regulation of β-cell mass, i.e. SOCS2 and TSC2. A critical role 
for the TSC2/mTOR pathway in regulating β-cells mass has been well reported, which 
further supports our hypothesis. Conditional deletion of TSC2 in pancreatic β-cells induced 
expansion of the β-cell mass, an action reversed by the mTOR inhibitor rapamycin [257]. We 
therefore hypothesized that TSC2 deletion increases tissue sensitivity to PRL, a hormone that 
regulates β-cell mass. This might open new doors in terms of the development of new 
approaches to expand the β-cell mass without a risk for oncogenic transformation induced by 
direct hormonal therapy. 
To substantiate the current findings in this study, further studies are needed to elucidate the 
precise role of SOCS2 in the regulation of β-cell mass, e.g. by measurements of β-cell mass 
after SOCS2-/- restricted to the islets. In summary, SOCS2-/- mice are more sensitive to GH/PRL 
and exhibit higher pancreatic GHR and PRLR levels, compared to control mice. GH/PRL 
stimulates pancreatic β-cell growth, survival and insulin production through the GHR/PRLR-
JAK2-STAT5 signaling pathway. 
 
4.2 PAPER II 
Role of PRLR in Lymphangioliomyomatosis 
LAM disease affects 30–40% of women with TSC disease, and TSC2 is a known negative 
regulator of mTOR. Loss of TSC1/TSC2 function in LAM leads to hyperactivation of 
mTORC1 and inhibition of autophagy, and such effects can be observed in TSC2-deficient 
LAM cells [258]. In this study, we analyzed the relationship between TSC2 and the PRL 
system in CRL2620 cells in which TSC2 levels were reduced using siRNA; in addition, we 
studied cell lines derived from LAM patients. A strong immunofluorescence signal for PRLR 
was observed at intracellular locations including the nucleus in both mouse-, and human 
derived cells (see Fig 2 and 3; Paper II). 
Activation of mTOR caused by TSC1/2 deficiency is one of several changes that occur in 
signaling pathways. Based on our finding that PRLR was increased in LAM/TSC cells, we 
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tested the short-term effects of PRL on intracellular protein phosphorylation by exposing 
human LAM/TSC cells to PRL. The most well studied PRL signaling pathway is the JAK2-
STAT pathway. We could not detect any STAT5 activation in these cells, whereas STAT3 
and ERK were activated by PRL (Figure 18).  
The STAT3 regulation by PRL observed in this study confirms the observations in previous 
studies, and the activation of this transcription factor seems to be of particular relevance for 
LAM cell growth [259]. STAT3 is known to participate in many normal cellular actions 
including differentiation, proliferation, and cell survival after stimulation by cytokines, 
growth factors, and hormones [260]. Our findings show that PRLRA reduces STAT3 and 
ERK activation even without PRL stimulation and this finding that only blockage of PRLR 
reduces STAT3 and ERK activation needs to be further investigated. One possibility is, 
however, that LAM cells might produce PRL themselves [163]. In lesions from LAM 
patients, both PRL and PRLR mRNA were found to be higher, compared to the surrounding 
vascular tissues and similar findings have been reported for other tumor tissues such as 
cancers of the breast and colon [261,262]. Our findings, along with similar previously 
reported results from Eker rat TSC2-/- cells, are in line with the hypothesis that PRL signaling 
has an important role in LAM. JAK2-STAT3 signaling pathway can be activated by many 
other cytokines. However, PRL could have a critical function in LAM cells given the results 
using the PRLRA. Importantly, we could not find any activation of STAT5, a finding that 
supports the concept that STAT3 activation is of key relevance for the dysregulated cell 
growth observed in LAM cells. 
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Figure 18. Human LAM cells express PRLR, and prolactin stimulates phosphorylation of 
STAT3 and ERK. LAM/TSC cells were exposed to different doses of PRLRA (20, 50, 200 
ng/ml) for 15 minutes, and subsequently the cells were exposed to 200 ng/ml PRL for 60 
minutes, or to PBS as a control. Protein extracts were prepared for western blot analysis and 
probed with antibodies for P-STAT3, STAT3, P-ERK and ERK. (A) Western blots to analyze 
PRLR in LAM/TSC control cells. (B) Western blot, using antibodies directed against P-
STAT3, STAT3, P-ERK and ERK in LAM/TSC cells. (C) Densitometric quantification of 
western blot signals, in which the Y-axis depicts the ratio between phosphorylated STAT3 and 
ERK to the total levels of each respective protein. 
 
STAT3 is a downstream mediator of Src. Src family kinases are tyrosine kinases which are 
key regulators of cellular proliferation, survival, motility and invasiveness. Reports have 
shown that accumulation of active Src kinase might lead to progression and metastasis of 
LAM cells, as for many other cancer cells [263]. It was recently shown that Src kinase 
activation promotes the migration and invasion of TSC2-/- cells, secondary to the upregulation 
of Snail transcription factor, which in turn suppresses E-cadherin expression [264]. 
Furthermore, we hypothesize that PRL may promote tumor growth in an autocrine/paracrine 
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manner in LAM lesions. Our study demonstrates the stimulatory dose-response effect of PRL 
on LAM/TSC cell proliferation in vitro, an effect blocked by PRLRA (Figure 19). In other 
tumor cells, antagonism of tumoral PRLR promotes autophagy-related cell death [164], 
supporting our findings, and suggesting that PRLRA might be a treatment option in LAM 
disease. 
 
 
 
Figure 19. Addition of exogenous PRL stimulates cell proliferation in a manner that can 
be blocked by PRLRA. LAM/TSC cells were cultured in different concentrations of serum 
(0%, 2%, 10%). Human PRL was added to sub-confluent cells at a concentration of 200 
ng/ml, with or without PRLRA (20, 50, 200 ng/ml). After 72 hours, cells were subject to the 
crystal violet assay. The X-axis depicts serum concentration and the Y-axis shows relative 
cell proliferation, as determined by absorbance at 600 nm. Each data point represents a 
triplicate assay. All values are +/- standard deviation, P-value <0.05. 
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Since the mTOR pathway is overactive in LAM disease, attempts have been made to treat 
LAM patients with rapamycin, a treatment recently approved by the US Food and Drug 
Administration (FDA). Treatment with rapamycin analogue improves lung function and 
reduces lesion size [180]. In concordance with these results, tumour re-growth and decline of 
lung function were associated with cessation of the same treatment [180]. An endocrine 
hormonal involvement (other than PRL) in LAM disease has been reported in several studies. 
LAM cells express both estrogen and progesterone receptors, and these cells seem to be 
estrogen responsive [265]. Estrogen is known to stimulate PRL secretion, and to stimulate 
ERK phosphorylation in TSC2-/- LAM cells. Due to this, estrogen antagonist treatment has 
been suggested and showed some efficacy in LAM; however this treatment was stopped due 
to the presence of side effects and the emergence of mTOR inhibitors [266]. Our study 
showed that PRL activates the MAPK pathway and phosphorylates ERK, and that this can be 
blocked with PRLRA. Taken together, it is tempting to hypothesize that PRLRA could 
provide an alternative to rapamycin, or could be used in combination for the treatment of 
LAM disease. Future studies are needed to explore this concept. 
In conclusion, we observed that reduction of TSC2 in LAM cells increases the PRLR levels, 
and that blocking this receptor by PRLRA may offer a new therapeutic angle for the 
treatment of LAM disease. 
 
4.3 PAPER III 
Stimulation of PRLR induces STAT-5 phosphorylation and cellular invasion in GBM 
A number of different alterations of cell signaling components have been found in GBM, 
ranging from receptor signaling to the loss of tumor suppressors. Relatively few studies on 
GBM have concerned the involvement of PRL. Moreover, previous studies have reported 
increased STAT and mTOR activity in GBM [189–193]. In this study, we investigated 
components of PRL system in cell models of GBM, and in histological tissue sections 
obtained from GBM patients.  
We found that PRLR is expressed at high levels in U251-MG cells. Immunofluorescence 
signals of PRLR expression were detected mostly in the perinuclear area. The phenomenon of 
perinuclear detection of PRLR has previously been seen in other cell types such as rat 
hepatocytes. A tissue microarray consisting of tissue samples from 32 GBM patients was 
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analyzed by IHC to detect the expression of PRLR. GBM lesions were found to express 
PRLR at different levels (negative, moderate, high-grade). Out of 32 sections, corresponding 
to 32 GBM cases, 66% were positive for PRLR. Expression of PRLR was not detected in the 
tissues of 34% (11 out of 32) of GBM patients, but it was detected at high-grade in GBM 
tumors of 50% (16 out of 32) of patients, and at moderate levels only in 16% (5 out of 32) of 
patients with the disease (Figure 20). 
 
Figure 20. Percentages of PRLR-negative and PRLR-positive cells in 32 GBM patients. 
Percentages of PRLR-positive cells were also shown in GBM patients with moderate and 
high-grade tumor. Percentages are shown with 95% confidence intervals. 
In line with our finding of PRLR expression in models of GBM, it is interesting to note that 
the choroid plexus is a rich source of PRLRs [267], and may have a role in the transport of 
PRL into the CNS. In addition, PRLR mRNA expression in human brain tissues has been 
reported in many gene expression databases. In recent yet unpublished work, we can 
corroborate such findings. In the present study, we found expression of PRLR in GBM cells 
and in brain tumor tissues. Taken together, evidences are accumulating that both PRL and its 
receptor are present in the brain, and we speculate that high-grade expression of PRLR could 
be related to the presence of GBM tumours. 
We investigated the short-term effects of PRL on intracellular signaling in U251-MG cells, 
and found that PRL increased STAT5 phosphorylation after 10 min, with a peak response 
seen after 20 min. However, STAT5 phosphorylation remained elevated for the whole 
duration of the experiment, i.e. 60 min (Figure 21A). The capacity of the antagonist to block 
PRL-induced STAT5 phosphorylation was subsequently studied by exposing cells to 
different concentrations of the PRLRA, followed by the addition of 100 ng/ml PRL. As 
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shown in (Figure 21C), pre-incubation with 100 ng/ml PRLRA (a concentration equal to that 
of PRL) dramatically blocked STAT5 phosphorylation, and this was also the case when the 
concentration of the antagonist was reduced 10-fold. The regulation of STAT5 by PRL in 
U251-MG cells observed in this study confirms previous studies which showed that PRLR 
regulates STAT5 tyrosine phosphorylation in different cells [268,269], and so activation of 
this transcription factor seems of particular relevance for GBM cells. Previous studies have 
also shown that phosphorylated STAT5 mediates the oncogenic effects of EGFR [270] in 
different tumor tissues, including GBM [271,272]. 
 
Figure 21. Effects of PRL and a PRLRA on STAT5 phosphorylation in U251-MG cells. 
Following protein extraction and gel electrophoresis, phospho-STAT5 (p-STAT5) and total 
STAT5 (STAT5) was analyzed using Western blotting. (A) U251-MG cells treated with PRL 
only (B) U251-MG cells were exposed to different concentrations of PRL (100, 200, 500 
ng/ml) for 20 minutes. To rule out any agonist activity of the PRLRA, cells were exposed to 
different concentrations of PRLRA (100, 300, 1000 ng/ml) for 15 min. (C) U251-MG cells 
were exposed to different doses of PRLRA for 5 min, and cells were then exposed to 100ng/ml 
PRL for 15 min. 
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GBM cells have been reported to produce PRL locally [199], and this would be in 
congruence with the finding of extra-pituitary PRL production in primates. In the literature, 
one study reported detection of PRL mRNA in human central nervous tissues [273], whereas 
another study showed PRL expression in GBM which was detectable by IHC, but not with 
real-time PCR [274]. It is possible that GBM represents a state of either increased PRL 
production, or increased PRL sensitivity. For example, in study II, we showed that loss of 
TSC2 function leads to increased PRL sensitivity in LAM cells. The mTOR system is 
regulated by TSC, and seems to be over-active in GBM [192,275,276], and there are several 
clinical cases which report the occurrence of GBM in TSC patients [196]. However, mTOR 
inhibitors have a limited efficacy on human GBM, which could partly be explained by the 
limited ability of rapamycin to cross the blood brain barrier in humans [185]. Possibly there is 
a need for combined targeted treatments, e.g. using both mTOR inhibitors and EGFR 
inhibitors to treat recurrent GBM. There are studies showing that combining rapamycin with 
an EGFR inhibitor improves clinical outcome in a small number of patients with recurrent 
GBM [277–279]. 
In this thesis, we found that two regulators of GH/PRL sensitivity, SOCS2 and TSC2. In the 
context of GBM, as mentioned before that SOCS1 and SOCS3 are abnormally expressed in 
different GBM cell lines, and this leads to augmented cell signaling through the ERK-MAPK 
pathway [194]. To this date, no SOCS2-related defect has been reported in GBM, however; 
low levels of SOCS2 have been involved in oncogenesis and has been identified as a 
biomarker in human colorectal cancer [280]. Low SOCS2 gene expression has been reported 
in other tumors of the breast, ovary and prostate. Since SOCS2 has been associated with 
GH/PRL signaling, and GHR/PRLR turnover; we speculate that SOCS2 involvement in 
GBM should be understood in terms of increased PRL sensitivity in GBM tissue in relation to 
the involvement of SOCS2/TSC2. 
It is further interesting to note that anti-angiogenic factors induce local production of PRL as 
a pro-survival response. As mentioned before, the combined application of the angiogenic 
inhibitors endostatin and tumastatin lead to the upregulation of PRLR in GBM in vivo, which 
in turn mediates tumor cell proliferation [199]. Another study has shown that PRL induces a 
dose-dependent increase in proliferation and survival of human U87-MG GBM cells [281]. 
Taken together, it is possible that GBM lesions can respond to agents that disrupt PRL 
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signals. Theoretically, a combination therapy of angiogenic inhibitors that up-regulate PRLR 
in GBM with a PRLRA could lead to therapeutic effects in GBM patients. The availability of 
a novel high-affinity PRLRA, employed in our study, that additionally lacks any residual 
agonistic properties, makes such studies feasible and of great interest.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This thesis had the aim to increase our understanding of factors that control GH and PRL 
receptor sensitivity. The main conclusions are summarized below: 
1. Deletion of SOCS2 partly protects against MLDSTZ-induced diabetes in mice. 
  
2. SOCS2-/- mice are more sensitive to GH/PRL, and exhibit higher pancreatic expression 
levels of GHR and PRLR, compared to WT mice.  
 
3. GH/PRL stimulates pancreatic insulin production through the JAK2-STAT5 signaling 
pathway and reduces palmitate induced lipo-toxicity in β-cells. 
 
4. Reduction of TSC2 in LAM cells increases PRLR levels. Blocking this receptor may 
offer a new therapeutic approach for LAM treatments. 
 
5. PRL is a potent mitogenic hormone that plays a critical role in LAM cell growth and 
invasion. 
 
6. GBM cells respond to PRL by STAT5 activation, and expression of PRLR can be 
detected in histological sections from GBM patients.  
 
The SOCS2-dependent increase of GH and PRL sensitivity in diabetes or other conditions 
raises questions on the importance of altered GH/PRL sensitivity, in addition to conditions 
related to over-, or under-production of these hormones. It may have a future potential to 
target GH/PRL sensitivity in cases where conventional hormone treatment fails because of 
reduced sensitivity. There are still many gaps in our knowledge that need to be filled, and this 
may in particular be the case for PRL, for which new data indicate that the hormone has a 
different profile of activity in humans, compared to animals. Future investigations, based on 
the findings in this thesis, are suggested by the following: 
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1. Further studies are needed to understand the role of SOCS2 in diabetes. The activity 
of GH and PRL, as well as of other cytokines, need to be examined. It is important to 
gain new knowledge about SOCS2 by creating tissue-specific SOCS2-/- mice. 
 
2. The effects of SOCS2-/- on β-cell viability needs to be studied in islet transplantation 
models.  
 
3. To understand more fully the molecular actions of SOCS2 and TSC2 on cytokine 
senstivity.  
 
4. Cell culture studies have limitations, and studies of homone activity in more complex 
in vivo systems are needed. 
 
5. The PRLRA is a new tool that will enable deeper investigations of PRL function in 
cells and animals. It is possible that the use of this antagonist can eventually lead to 
novel treatments in human PRL-dependent hyper-proliferative conditions.  
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6 GENERAL SUMMARY 
Hormones mediate an important part of the crosstalk between different organs in the body. 
Hormones are secreted from specialized glands in the body and travel through the blood to 
reach their target cells to elicit the required responses through binding to respective receptors. 
Growth factors have a similar mode of action, but normally act in proximity to their site of 
production. In this study, we have focused on two hormones, GH and PRL. Both GH and 
PRL are secreted from the pituitary gland, but it is becoming increasingly clear that extra-
pituitary PRL production occurs in many tissues. GH and PRL have distinct biological 
actions: GH regulates longitudinal growth, regeneration and ageing, whereas PRL is the main 
lactogenic hormone that also exerts actions on the gonadal axis. These hormones share 
structural similarities, and exert their action using similar signaling systems.  
Given the overall general significance of hormone sensitivity, this thesis is primarily focused 
on the regulation of sensitivity for GH and PRL in different disease models. Altered 
sensitivity to hormones might be the cause and the mechanistic basis of disease. The 
sensitivity of a cell to GH and PRL is linked to the expression levels of GHR and PRLR in 
that cell. GH binds to both GH and PRL receptors, whereas PRL only binds to the PRLR. 
Binding initiates a signaling cascade inside the cell, which leads to the expression of hormone 
responsive genes. Regulation of GH and PRL sensitivity by two different genes, SOCS2 and 
TSC2, has been studied in this thesis. Alteration or deletion of these two genes leads to the 
reduced degradation of the GHR and PRLR, and thereby an increase in tissue sensitivity to 
these hormones. 
In study I, the role of SOCS2 in diabetes was investigated. Mice in which the SOCS2 gene 
was deleted (SOCS2-/- mice) were injected with streptozotocin (a chemical that destroys the β-
cells in the pancreas) in order to induce diabetes. We found that, compared to normal mice, 
SOCS2-/- mice were more resistant to streptozotocin. Subsequently, low levels of SOCS2 
allow for a better survival of β-cells. It is tempting to speculate that increased GH/PRL 
sensitivity is an important factor to explain this observation.   
In studies II and III, we studied the role of PRL in two different tumors, LAM and GBM. 
LAM is a benign destructive tumor affecting smooth muscle cells in fertile females, while 
GBM is an aggressive brain tumor. LAM and GBM tumor cells were found to be PRL-
sensitive and to express PRLR, and activation of PRLR induced the JAK-STAT signaling 
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pathway. In addition, cell invasion of these tumor cells was stimulated by PRL. IHC was used 
to demonstrate the presence of PRLR in LAM and GBM. A reagent (PRLRA) that blocks the 
PRLR was produced and this compound reduced PRL’s effects in cells.  
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